Important Studies of Deferoxamine Therapy in Thalassemia
| Finding . | Date . | Reference . |
|---|---|---|
| IV and intramuscular administration promotes iron excretion | 1962 | 58, 59 |
| Subcutaneous administration induces iron excretion | 1964 | 60 |
| Intramuscular therapy stabilizes hepatic iron, arrests hepatic fibrosis in transfused patients | 1974 | 61 |
| Supplemental ascorbic acid increases deferoxamine-induced urinary iron excretion | 1974 | 62, 248 |
| 24-h IV infusions calculated to achieve iron balance | 1976 | 62, 63 |
| 24-h subcutaneous infusions calculated to achieve iron balance | 1976 | 64, 65 |
| Portable infusion pumps used to administer 24-h subcutaneous infusions | 1976 | 64, 65 |
| 12-h infusions calculated to achieve iron balance | 1978 | 64 |
| Long-term subcutaneous therapy reduces hepatic iron concentration | 1981 | 98, 99 |
| Significant fecal iron excretion induced by deferoxamine | 1982 | 66 |
| Long-term subcutaneous therapy reduces incidence of cardiac disease in compliant patients | 1985 | 83 |
| Early therapy extends survival in young cohorts of patients | 1989 | 23 |
| IV and subcutaneous therapy normalizes hepatic iron concentration | 1989 | 102 |
| Regular therapy started before age 10 years reduces incidence of gonadal dysfunction | 1990 | 137 |
| Long-term therapy extends survival free of glucose intolerance and cardiac disease | 1994 | 91, 92 |
| Finding . | Date . | Reference . |
|---|---|---|
| IV and intramuscular administration promotes iron excretion | 1962 | 58, 59 |
| Subcutaneous administration induces iron excretion | 1964 | 60 |
| Intramuscular therapy stabilizes hepatic iron, arrests hepatic fibrosis in transfused patients | 1974 | 61 |
| Supplemental ascorbic acid increases deferoxamine-induced urinary iron excretion | 1974 | 62, 248 |
| 24-h IV infusions calculated to achieve iron balance | 1976 | 62, 63 |
| 24-h subcutaneous infusions calculated to achieve iron balance | 1976 | 64, 65 |
| Portable infusion pumps used to administer 24-h subcutaneous infusions | 1976 | 64, 65 |
| 12-h infusions calculated to achieve iron balance | 1978 | 64 |
| Long-term subcutaneous therapy reduces hepatic iron concentration | 1981 | 98, 99 |
| Significant fecal iron excretion induced by deferoxamine | 1982 | 66 |
| Long-term subcutaneous therapy reduces incidence of cardiac disease in compliant patients | 1985 | 83 |
| Early therapy extends survival in young cohorts of patients | 1989 | 23 |
| IV and subcutaneous therapy normalizes hepatic iron concentration | 1989 | 102 |
| Regular therapy started before age 10 years reduces incidence of gonadal dysfunction | 1990 | 137 |
| Long-term therapy extends survival free of glucose intolerance and cardiac disease | 1994 | 91, 92 |